These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35745810)

  • 1. Pneumococcal Surface Protein A-Hybrid Nanoparticles Protect Mice from Lethal Challenge after Mucosal Immunization Targeting the Lungs.
    Figueiredo DB; Kaneko K; Rodrigues TDC; MacLoughlin R; Miyaji EN; Saleem I; Gonçalves VM
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection.
    Rodrigues TC; Oliveira MLS; Soares-Schanoski A; Chavez-Rico SL; Figueiredo DB; Gonçalves VM; Ferreira DM; Kunda NK; Saleem IY; Miyaji EN
    PLoS One; 2018; 13(1):e0191692. PubMed ID: 29360883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro.
    Kaneko K; Miyaji EN; Gonçalves VM; Ferreira DM; Solórzano C; MacLoughlin R; Saleem I
    Int J Pharm; 2021 Apr; 599():120407. PubMed ID: 33675930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immune responses in guinea pigs by intranasal delivery with different nanoparticles-loaded FMDV DNA vaccine.
    Zheng H; Pan L; Lv J; Zhang Z; Wang Y; Hu W; Liu X; Zhou P; Wang Y; Zhang Y
    Microb Pathog; 2020 Feb; 142():104061. PubMed ID: 32061916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine Against
    Du X; Xue J; Jiang M; Lin S; Huang Y; Deng K; Shu L; Xu H; Li Z; Yao J; Chen S; Shen Z; Feng G
    Int J Nanomedicine; 2021; 16():1819-1836. PubMed ID: 33707942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicistronic DNA vaccine macromolecule complexed with poly lactic-co-glycolic acid-chitosan nanoparticles enhanced the mucosal immunity of Labeo rohita against Edwardsiella tarda infection.
    Leya T; Ahmad I; Sharma R; Tripathi G; Kurcheti PP; Rajendran KV; Bedekar MK
    Int J Biol Macromol; 2020 Aug; 156():928-937. PubMed ID: 32289420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus.
    Rodrigues TC; Figueiredo DB; Gonçalves VM; Kaneko K; Saleem IY; Miyaji EN
    J Control Release; 2024 Apr; 368():184-198. PubMed ID: 38395155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel naltrexone hydrochloride nanovaccine based on chitosan nanoparticles promotes induction of Th1 and Th17 immune responses resulting in protection against Toxoplasma gondii tachyzoites in a mouse model.
    Khorshidvand Z; Khosravi A; Mahboobian MM; Larki-Harchegani A; Fallah M; Maghsood AH
    Int J Biol Macromol; 2022 May; 208():962-972. PubMed ID: 35346684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Em14-3-3 delivered by PLGA and chitosan nanoparticles conferred improved protection in chicken against Eimeria maxima.
    Haseeb M; Huang J; Lakho SA; Yang Z; Hasan MW; Ehsan M; Aleem MT; Memon MA; Ali H; Song X; Yan R; Xu L; Li X
    Parasitol Res; 2022 Feb; 121(2):675-689. PubMed ID: 34984543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization.
    Mittal A; Raber AS; Schaefer UF; Weissmann S; Ebensen T; Schulze K; Guzmán CA; Lehr CM; Hansen S
    Vaccine; 2013 Jul; 31(34):3442-51. PubMed ID: 23290836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against
    Wiedinger K; Pinho D; Bitsaktsis C
    Ther Adv Vaccines; 2017 Feb; 5(1):15-24. PubMed ID: 28344805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine.
    Zhao K; Zhang Y; Zhang X; Shi C; Wang X; Wang X; Jin Z; Cui S
    Int J Nanomedicine; 2014; 9():4609-19. PubMed ID: 25356070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
    Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
    Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics.
    Ünal S; Doğan O; Aktaş Y
    Beilstein J Nanotechnol; 2022; 13():1393-1407. PubMed ID: 36483636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.